^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    5T4-targeted antibody-drug conjugate

    Related drugs:
    7d
    Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, NeoTX Therapeutics Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TPBG (Trophoblast Glycoprotein)
    |
    HER-2 negative
    |
    Imfinzi (durvalumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
    11d
    ACR246-101: An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=77, Recruiting, Hangzhou Adcoris Biopharmacy Co., Ltd | Trial completion date: Jan 2026 --> Nov 2026 | Trial primary completion date: Jun 2025 --> May 2026
    Trial completion date • Trial primary completion date
    4ms
    Preclinical characterization of XB010: a novel antibody-drug conjugate for the treatment of solid tumors that targets tumor-associated antigen 5T4. (PubMed, Mol Cancer Ther)
    XB010 is a novel anti-5T4 ADC that exhibits potent anti-tumor activity, inhibiting cancer cell growth in vitro and tumor growth in various in vivo models, with an acceptable toxicity profile. These findings support the evaluation of XB010 in clinical studies.
    Preclinical • Journal
    |
    TPBG (Trophoblast Glycoprotein)
    9ms
    Naptumomab Estafenatox in Combination with Durvalumab in Subjects with Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. (clinicaltrials.gov)
    P1, N=120, Recruiting, NeoTX Therapeutics Ltd. | Active, not recruiting --> Recruiting | N=60 --> 120 | Trial completion date: Oct 2026 --> Mar 2027 | Trial primary completion date: Oct 2026 --> Mar 2027
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TPBG (Trophoblast Glycoprotein)
    |
    HER-2 negative
    |
    Imfinzi (durvalumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
    11ms
    5-STAR 1-01: First in Human Study of TUB-030 in Patients with Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=130, Recruiting, Tubulis GmbH | Not yet recruiting --> Recruiting
    Enrollment open
    1year
    ACR246-101: An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients with Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=77, Recruiting, Hangzhou Adcoris Biopharmacy Co., Ltd | Not yet recruiting --> Recruiting | Initiation date: Mar 2024 --> Oct 2024 | Trial primary completion date: Jan 2025 --> Jun 2025
    Enrollment open • Trial initiation date • Trial primary completion date • Metastases
    1year
    A Study of JK06 in Patients with Unresectable Locally Advanced or Metastatic Cancer (clinicaltrials.gov)
    P1/2, N=155, Recruiting, Salubris Biotherapeutics Inc
    New P1/2 trial • Metastases
    1year
    First in Human Study of TUB-030 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=130, Not yet recruiting, Tubulis GmbH
    New P1/2 trial
    over1year
    Study of XB010 in Subjects With Solid Tumors (clinicaltrials.gov)
    P1, N=350, Recruiting, Exelixis
    New P1 trial • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab)
    over1year
    Study of ASN004 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=19, Completed, Kirilys Therapeutics Inc. | Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> May 2024
    Trial completion • Trial completion date • Metastases
    |
    TPBG (Trophoblast Glycoprotein)
    |
    KRLS-004
    over1year
    Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers (clinicaltrials.gov)
    P1, N=0, Withdrawn, Weill Medical College of Cornell University | N=30 --> 0 | Initiation date: Jun 2023 --> Nov 2023 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2024 --> Dec 2025
    Enrollment change • Trial initiation date • Trial withdrawal • Trial primary completion date • Combination therapy
    |
    Keytruda (pembrolizumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
    almost2years
    Study of ASN004 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, Kirilys Therapeutics Inc. | Recruiting --> Active, not recruiting | N=45 --> 19 | Trial completion date: Mar 2027 --> Sep 2024 | Trial primary completion date: Mar 2026 --> Jun 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    TPBG (Trophoblast Glycoprotein)
    |
    TPBG expression
    |
    KRLS-004